Leon Chen Ph.D.



Leon Chen has been a Venture Partner with OrbiMed Advisors since 2013 where he plays a dual role both as founder and CEO of biotechnology companies in the OrbiMed portfolio as well as investing private healthcare companies.

He started his career as a co-founder of KAI Pharmaceuticals, a company he started based on his graduate work at Stanford University.  Amgen acquired KAI in 2012, which led to the approval of Parsabiv, a novel therapy for the treatment of secondary hyperparathyroidism.

In his career Leon has started numerous biotechnology companies both as an Entrepreneur in Residence at Venrock and as a Venture Partner at OrbiMed in a variety of therapeutic areas. As a venture capitalist, he has invested and serves on the board of numerous therapeutic and diagnostic companies.

Leon holds a B.A. in Biochemistry from the University of California at Berkeley, a Ph.D. in Molecular Pharmacology at Stanford, and an M.B.A. from the Stanford Graduate School of Business. He also serves as an Adjunct Professor in the Chemical and Systems Biology Department at the Stanford School of Medicine.